{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ibanez J"],"funding":["NCI NIH HHS","NINDS NIH HHS"],"pagination":["101297"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10694756"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(11)"],"pubmed_abstract":["Lack of targetable antigens is a key limitation for developing successful T cell-based immunotherapies. Members of the unfolded protein response (UPR) represent ideal immunotherapy targets because the UPR regulates the ability of cancer cells to resist cell death, sustain proliferation, and metastasize. Glucose-regulated protein 78 (GRP78) is a key UPR regulator that is overexpressed and translocated to the cell surface of a wide variety of cancers in response to elevated endoplasmic reticulum (ER) stress. We show that GRP78 is highly expressed on the cell surface of multiple solid and brain tumors, making cell surface GRP78 a promising chimeric antigen receptor (CAR) T cell target. We demonstrate that GRP78-CAR T cells can recognize and kill GRP78+ brain and solid tumors in vitro and in vivo. Additionally, our findings demonstrate that GRP78 is upregulated on CAR T cells upon T cell activation; however, this expression is tumor-cell-line specific and results in heterogeneous GRP78-CAR T cell therapeutic response."],"journal":["Cell reports. Medicine"],"pubmed_title":["GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells."],"pmcid":["PMC10694756"],"funding_grant_id":["P30 CA021765","T32 CA272387","R01 NS122859","P01 CA096832","R50 CA211481"],"pubmed_authors":["Yi Z","Tian L","Krenciute G","Nevitt C","Ward M","Hebbar N","Chiang J","Sheppard H","Ibanez J","Velasquez MP","Thanekar U","Houke H","Mack SC"],"additional_accession":[]},"is_claimable":false,"name":"GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells.","description":"Lack of targetable antigens is a key limitation for developing successful T cell-based immunotherapies. Members of the unfolded protein response (UPR) represent ideal immunotherapy targets because the UPR regulates the ability of cancer cells to resist cell death, sustain proliferation, and metastasize. Glucose-regulated protein 78 (GRP78) is a key UPR regulator that is overexpressed and translocated to the cell surface of a wide variety of cancers in response to elevated endoplasmic reticulum (ER) stress. We show that GRP78 is highly expressed on the cell surface of multiple solid and brain tumors, making cell surface GRP78 a promising chimeric antigen receptor (CAR) T cell target. We demonstrate that GRP78-CAR T cells can recognize and kill GRP78+ brain and solid tumors in vitro and in vivo. Additionally, our findings demonstrate that GRP78 is upregulated on CAR T cells upon T cell activation; however, this expression is tumor-cell-line specific and results in heterogeneous GRP78-CAR T cell therapeutic response.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-05-29T00:41:11.341Z","creation":"2025-04-06T05:38:08.617Z"},"accession":"S-EPMC10694756","cross_references":{"pubmed":["37992682"],"doi":["10.1016/j.xcrm.2023.101297"]}}